Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | terminated | Phase 1 | 18 | Celldex TherapeuticsINDUSTRY | 1 | Apr 30, 2018 | clinicaltrials |
| NCT02884479 | An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study | unknown | Phase 1 / Phase 2 | 75 | SciClone Pharmaceuticals International (Cayman) Development LimitedINDUSTRY |
| 1 |
| Apr 25, 2018 |
| clinicaltrials |
| NCT01588145 | Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients | completed | Phase 1 / Phase 2 | 273 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Apr 24, 2018 | clinicaltrials |
| NCT00901537 | Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer | terminated | Phase 1 | 8 | Loma Linda UniversityOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT01998126 | Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer | completed | Phase 1 | 14 | University of UtahOTHER | 1 | Apr 2, 2018 | clinicaltrials |
| NCT01520389 | Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | completed | Phase 1 | 112 | Merrimack PharmaceuticalsINDUSTRY | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00923312 | Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 46 | CureVacINDUSTRY | 2 | Mar 20, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and ClydeOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT01809210 | Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer(SELECT-3) | completed | Phase 1 | 55 | AstraZenecaINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT00268151 | Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer | terminated | Phase 1 | 24 | University of LouisvilleOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT02342353 | Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) | terminated | Phase 1 | 8 | Washington University School of MedicineOTHER | 1 | Feb 27, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT03446911 | Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery | unknown | Phase 1 / Phase 2 | 20 | Amsterdam UMC, location VUmcOTHER | 0 | Feb 27, 2018 | clinicaltrials |
| NCT01090830 | Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer(HCH003) | terminated | Phase 1 / Phase 2 | 7 | Holy Cross Hospital, FloridaOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00399789 | A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 121 | AEterna ZentarisINDUSTRY | 1 | Feb 22, 2018 | clinicaltrials |
| NCT02393209 | Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 14 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Feb 7, 2018 | clinicaltrials |
| NCT02151721 | Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer(VICTORY-J) | unknown | Phase 1 | 12 | Kanazawa UniversityOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT00372515 | High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations | completed | Phase 1 | 7 | David M. Jackman, MDOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT00455052 | A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Mersana TherapeuticsINDUSTRY | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01574222 | A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer(VTNSCLC) | terminated | Phase 1 | 1 | VA Office of Research and DevelopmentFED | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02018523 | Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer | terminated | Phase 1 | 7 | Jun ZhangOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02014337 | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | completed | Phase 1 | 37 | Corcept TherapeuticsINDUSTRY | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00599755 | Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3) | completed | Phase 1 | 68 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 16, 2018 | clinicaltrials |
| NCT01336842 | Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | completed | Phase 1 | 23 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00794547 | Phase I/II Calcitriol in Lung Cancer | terminated | Phase 1 / Phase 2 | 34 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT02172846 | Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer | completed | Phase 1 | 23 | Washington University School of MedicineOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00093756 | Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2017 | clinicaltrials |
| NCT00667082 | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | completed | Phase 1 | 22 | CelgeneINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00654758 | A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 33 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01225302 | A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 12 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00528281 | A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 4 | Nov 17, 2017 | clinicaltrials |
| NCT00619424 | A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors | completed | Phase 1 | 58 | GlaxoSmithKlineINDUSTRY | 2 | Nov 17, 2017 | clinicaltrials |
| NCT01746810 | IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03201146 | Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | unknown | Phase 1 / Phase 2 | 48 | West China HospitalOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00678977 | A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors | completed | Phase 1 | 22 | GlaxoSmithKlineINDUSTRY | 2 | Nov 14, 2017 | clinicaltrials |
| NCT00866528 | Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 2 | Nov 13, 2017 | clinicaltrials |
| NCT00946673 | Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer | completed | Phase 1 | 17 | Stanford UniversityOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT01995188 | A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer | completed | Phase 1 | 41 | Genentech, Inc.INDUSTRY | 1 | Oct 4, 2017 | clinicaltrials |
| NCT03001609 | Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC | completed | Phase 1 | 7 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Oct 3, 2017 | clinicaltrials |
| NCT03198923 | Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer | unknown | Phase 1 | 30 | Wenxiang WangOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT01727076 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT03282435 | Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody | unknown | Phase 1 | 30 | Dalian UniversityOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | terminated | Phase 1 | 5 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT02924233 | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Symphogen A/SINDUSTRY | 0 | Aug 28, 2017 | clinicaltrials |
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | completed | Phase 1 | 13 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01733589 | Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC | completed | Phase 1 / Phase 2 | 73 | Zhejiang Cancer HospitalOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT03205930 | Neo-MASCT Immunotherapy for Advanced NSCLC. | unknown | Phase 1 / Phase 2 | 20 | The First People's Hospital of LianyungangOTHER | 1 | Jul 5, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Apr 30, 2018source: clinicaltrials